Sena Sayood

Sena Sayood

Auto-generated profile, based on publicly available information

Sena Sayood

Washington University in St Louis

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JWJohn A Wildenthal
John A Wildenthal
AAAndrew Atkinson
Andrew Atkinson
SLSophia Lewis
Sophia Lewis
SSSena Sayood
Sena Sayood
NNNathanial S Nolan
Nathanial S Nolan
LMLaura R Marks
Laura R Marks
Staphylococcus aureus represents the leading cause of complicated bloodstream infections among persons who inject drugs (PWID). Standard of care (SOC) intravenous (IV) antibiotics result in high rates of treatment success but are not feasible for some PWID. Transition to oral antibiotics may represent an alternative treatment option. We evaluated all adult patients with a history of injection drug use hospitalized from January 2016 through December 2021 with complicated S. aureus bloodstream infections, including infective endocarditis, epidural abscess, vertebral osteomyelitis, and septic arthritis. Patients were compared by antibiotic treatment (standard of care intravenous [SOC IV] antibiotics, incomplete IV therapy, or transition from initial IV to partial oral) using the primary composite endpoint of death or readmission from microbiologic failure within 90 days of discharge. Patients who received oral antibiotics after an incomplete IV antibiotic course were significantly less likely to experience microbiologic failure or death than patients discharged without oral antibiotics (P < .001). There was no significant difference in microbiologic failure rates when comparing patients who were discharged on partial oral antibiotics after receiving at least 10 days of IV antibiotics with SOC regimens (P > .9). Discharge of PWID with partially treated complicated S. aureus bacteremias without oral antibiotics results in high rates of morbidity and should be avoided. For PWID hospitalized with complicated S. aureus bacteremias who have received at least 10 days of effective IV antibiotic therapy after clearance of bacteremia, transition to oral antibiotics with outpatient support represents a potential alternative if the patient does not desire SOC IV antibiotic therapy.

5 October 2023 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
GSGiorgia Sulis
Giorgia Sulis
SSSena Sayood
Sena Sayood
SGSUMANTH GANDRA
SUMANTH GANDRA
Antibiotic overuse is a pressing global health concern, particularly in low- and middle-income countries (LMICs) where there is limited access to quality healthcare and insufficient regulation of antibiotic dispensation. This perspective piece highlights the challenges of antibiotic overuse in LMICs and provides insights into potential solutions to address this issue. This perspective explores key factors contributing to antibiotic overuse in LMICs, encompassing weak healthcare infrastructure, limited access to quality services, and deficiencies in diagnostic capabilities. It discusses regulatory frameworks to curb non-prescription sales, the role of accessible point-of-care diagnostic tools, challenges in implementing effective stewardship programs, the expanded use of vaccines, and the importance of health systems, hygiene, and sanitation. In this article, we emphasize the need for a comprehensive approach involving collaboration among healthcare professionals, policymakers, researchers, and educators. We underscore the importance of improving healthcare infrastructure, enhancing access to quality services, and strengthening diagnostic capabilities. The article also highlights the significance of education and awareness in promoting responsible antibiotic use, the role of regulatory measures, the expanded utilization of vaccines, and the need for international collaboration to address the challenges of antibiotic overuse in LMICs.

1 May 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
SSSena Sayood
Sena Sayood
MDMichael J. Durkin
Michael J. Durkin
The justification for antibiotic stewardship is not controversial. Antibiotics are used unnecessarily in all aspects of human and animal health; unnecessary ant

15 April 2021 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
SSSena J. Sayood
Sena J. Sayood
MBMargaret Botros
Margaret Botros
KSKatie J. Suda
Katie J. Suda
RFRandi Foraker
Randi Foraker
MDMichael J. Durkin
Michael J. Durkin

10 November 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSSena Sayood
Sena Sayood
LMLaura R Marks
Laura R Marks
RPRupa Patel
Rupa Patel
NNNathanial S Nolan
Nathanial S Nolan
SLStephen Y Liang
Stephen Y Liang
MDMichael J. Durkin
Michael J. Durkin
We interviewed persons who inject drugs (PWID) to understand perceptions of pre-exposure prophylaxis (PrEP) to prevent HIV infection. Knowledge of PrEP was poor. Patients felt that PrEP was for sexual intercourse rather than injection drug use, and PWID managed on medications for opioid use disorder felt that they had no need for PrEP.

11 December 2025 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
SSSena Sayood
Sena Sayood
ENElizabeth Neuner
Elizabeth Neuner
RDRebekah Dumm
Rebekah Dumm
SGSUMANTH GANDRA
SUMANTH GANDRA
SUMMARY: The penem and carbapenem antibiotics provide some of the broadest spectrum coverage available and generally should only be used when narrower options are unavailable. The majority of available carbapenems can only be administered parenterally, but two orally administered penems (faropenem and sulopenem) and one orally administered carbapenem (tebipenem) are in increased use due to approvals in new markets. These oral agents have a spectrum of activity similar to widely used parenteral carbapenems but are simpler to administer than intravenous agents and will likely experience rapid increases in their rates of use as they are approved in new markets. In this review, we discuss their spectra of activity, pharmacokinetics, pharmacodynamics, clinical efficacy, toxicity, antimicrobial stewardship considerations, and potential clinical applications.